Patents in place.15 Sep 2025 11:00
Renalytix and patented
All
Images
Videos
News
Short videos
Shopping
Forums
Web
Books
Maps
Flights
Finance
Search tools
Feedback
AI Overview
+3
Yes, Renalytix has patents for their kidney disease diagnostics platform, KidneyIntelX, with the US Patent Office allowing key claims in October 2023 that extend the use of their primary blood biomarker, sTNFR1, to all diabetes patients for identifying risk of progressive kidney disease. The company also actively builds its intellectual property portfolio through its own efforts and by in-licensing additional opportunities, including agreements with the Joslin Diabetes Center for novel biomarkers.